Skip to main content

Antibacterial (Nano)medicines Development

Objective

Despite the investment of billions of euros, there has been an inexorable decline in the discovery of new antibiotics over the last decades. In this individual fellowship (IF) application we propose a strategy to develop bacterial histidine-kinase (HK) inhibitors targeted at the catalytic and ATP-biding domain (CA) as novel broad-spectrum antibacterial (nano)medicines. Furthermore, putative mechanism of resistance to HK inhibitors and known antibiotics will be studied and novel antibacterial drug targets will be identified by using transposon insertion mutant libraries (Tn-libraries) to identify mutations involved in intrinsic resistance to antibiotics and/or leading to increased sensitivity to existing antibiotics in multi-drug resistant (MDR) strains.

Field of science

  • /natural sciences/biological sciences/genetics and heredity/mutation
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/drug resistance/multidrug resistance

Call for proposal

H2020-MSCA-IF-2014
See other projects for this call

Funding Scheme

MSCA-IF-EF-ST - Standard EF

Coordinator

WAGENINGEN UNIVERSITY
Address
Droevendaalsesteeg 4
6708 PB Wageningen
Netherlands
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 165 598,80